Trials / Active Not Recruiting
Active Not RecruitingNCT03777969
Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients
Precise Prediction System for Clinical Endpoint Events of Chronic Hepatitis B Patients in the Ear of Antiviral Therapy
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,000 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A total of 2000 chronic hepatitis B (CHB) patients with liver biopsy performed at least 1 year after antiviral therapy are enrolled. All the patients will receive original antiviral treatment for the following 10 years. Patients will be assessed at baseline and at every six months for blood count, liver function test, alpha fetoprotein (AFP), prothrombin time, liver ultrasonography, liver stiffness measurement (LSM), Hepatitis B virus (HBV) DNA and HBV serological markers. HBV-related endpoint events, including cirrhosis decompensations (ascites, esophageal variceal bleeding and hepatic encephalopathy), hepatocellular carcinoma (HCC), liver transplantation and liver-related death, will be collected during follow-up.
Detailed description
No.
Conditions
Timeline
- Start date
- 2018-06-29
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
- First posted
- 2018-12-19
- Last updated
- 2022-09-06
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03777969. Inclusion in this directory is not an endorsement.